Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies.
Norsworthy, Kelly J; Cho, Eunpi; Arora, Jyoti; Kowalski, Jeanne; Tsai, Hua-Ling; Warlick, Erica; Showel, Margaret; Pratz, Keith W; Sutherland, Lesley A; Gore, Steven D; Ferguson, Anna; Sakoian, Sarah; Greer, Jackie; Espinoza-Delgado, Igor; Jones, Richard J; Matsui, William H; Smith, B Douglas.
; 49: 90-7, 2016 10.
Artigo em Inglês | MEDLINE | ID: mdl-27619199
Inhaled GM-CSF for Pulmonary Alveolar Proteinosis.
Practical Application of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Patients with Wounds.
Sargramostim (GM-CSF) for induction of remission in Crohn's disease.
Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
New emerging applications of molgramostim in acute myeloid leukaemia.
Commanding CNS Invasion: GM-CSF.
GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation.
Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes.
Clozapine-Associated Agranulocytosis Treatment With Granulocyte Colony-Stimulating Factor/Granulocyte-Macrophage Colony-Stimulating Factor: A Systematic Review.